Evidence from this study suggests that I-FABP, L-FABP, and defensins 5 and 6 may not serve as potential early biomarkers for MASLD diagnosis, but they can be used to describe organ damage such as liver and intestinal damage in children with MASLD. The gene discussed is FABP1; the disease is metabolic dysfunction-associated steatotic liver disease.